跳到正文
openFDA 已分级药品召回执法报告·· 19 天前精选AI 评分64

FDA 执法报告 D-0111-2027:Brandywine 茶碱缓释片 200 mg 因第三方实验室稳定性试验中断被列为 II 类召回

FDA drug enforcement D-0111-2027: Brandywine Pharmaceuticals, LLC — CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

AI 导读

openFDA 执法报告 D-0111-2027 显示,Brandywine Pharmaceuticals 的茶碱缓释片 200 mg(批号 405620,有效期 2028 年 3 月 31 日)因第三方实验室稳定性试验中断的 CGMP 偏差,被列为 II 类自愿召回。

推荐理由

记录显示该企业自愿召回的分类结果为 II 类,原因指向第三方实验室稳定性试验中断,可据此核对批次与分销范围。

正文 · AI 翻译

FDA 药品召回执法报告 — D-0111-2027

报告发布日期:2026-11-04。这是执法报告日期,不是召回启动日期。

范围:一条已分类的药品召回记录;event_id 可能归组多个产品。无召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿,也不是新的执法认定。

openFDA 数据集每周更新。报告状态不是实时召回状态,不得用于跟踪召回生命周期。以下其他日期保留其各自名称所对应的含义。

完整官方产品记录(包括 openFDA 统一标识符):

{

"address_1": "600 W Strasburg Rd",

"address_2": "",

"center_classification_date": "20261029",

"city": "West Chester",

"classification": "Class II",

"code_info": "Lot: 405620, Expiry: 03/31/2028.",

"country": "United States",

"distribution_pattern": "Nationwide within U.S",

"event_id": "100038",

"initial_firm_notification": "Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",

"more_code_info": "",

"openfda": {},

"postal_code": "19382-1955",

"product_description": "Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.",

"product_quantity": "1,332 100-count bottles",

"product_type": "Drugs",

"reason_for_recall": "CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory",

"recall_initiation_date": "20261006",

"recall_number": "D-0111-2027",

"recalling_firm": "Brandywine Pharmaceuticals, LLC",

"report_date": "20261104",

"state": "PA",

"status": "Ongoing",

"voluntary_mandated": "Voluntary: Firm initiated"

}

来源:openFDA 已分级药品召回执法报告 · api.fda.gov